How to Buy Beyond Air, Inc. (XAIR) Stock in the UK – Complete Guide 2025

Introduction to Beyond Air, Inc. (XAIR)

Beyond Air, Inc. (XAIR) is a clinical-stage medical device and biopharmaceutical company that has caught the attention of healthcare investors worldwide. Trading on the NASDAQ Capital Market, Beyond Air focuses on developing inhaled nitric oxide (iNO) therapies for respiratory and other diseases. For UK investors looking to diversify their portfolios with innovative healthcare stocks, XAIR presents an intriguing opportunity in the growing medical device sector.

The company’s primary focus is on developing LungFit™, a proprietary inhaled nitric oxide generator and delivery system. This technology has potential applications in treating various respiratory conditions, making it particularly relevant in today’s healthcare landscape. With a current market capitalisation of $19.70 million (approximately £15.8 million), Beyond Air represents a small-cap investment opportunity with significant growth potential.

Current Stock Performance Analysis

As of the latest trading session, Beyond Air (XAIR) is experiencing remarkable momentum with some impressive performance metrics that UK investors should consider:

Key Performance Metrics

Metric	Value	GBP Equivalent
Current Price	$3.77 USD	£3.02
Daily Change	+70.59%	N/A
Market Cap	$19.70M USD	£15.8M
52-Week Low	$2.02 USD	£1.62
52-Week High	$13.52 USD	£10.84
Monthly Performance	+25.67%	N/A

Performance Analysis

The stock’s recent performance shows extraordinary volatility, with a single-day gain of 70.59% indicating significant market interest or news-driven momentum. The monthly performance of 25.67% suggests sustained investor interest over the past month. However, it’s crucial to note that the stock is currently trading well below its 52-week high of $13.52, indicating previous periods of much higher valuation.

The absence of a P/E ratio typically indicates that the company is not currently profitable, which is common for clinical-stage biopharmaceutical companies that are still in the development phase of their products.

Step-by-Step Guide: How to Buy XAIR Stock from the UK

Step 1: Choose a UK Broker

Select a reputable UK broker that offers access to US markets. Consider factors such as commission fees, minimum deposits, and available account types (particularly ISA eligibility for tax benefits).

Step 2: Open and Fund Your Account

Complete the account opening process, which typically involves:

• Providing personal identification documents
• Completing know-your-customer (KYC) requirements
• Making an initial deposit in GBP
• Waiting for account approval (usually 1-3 business days)

Step 3: Navigate to US Markets

Once your account is active, navigate to the US markets section of your broker’s platform and search for “XAIR” or “Beyond Air, Inc.”

Step 4: Place Your Order

Decide on your order type:

• Market Order: Buy immediately at current market price
• Limit Order: Set a specific price at which you want to buy
• Stop-Loss Order: Set a price to automatically sell if the stock falls

Step 5: Monitor Your Investment

Keep track of your investment through your broker’s platform and stay updated with company news and financial reports.

Best UK Brokers for Buying XAIR Stock

eToro

• Commission: 0% on stocks
• Minimum Deposit: £50
• Key Features: Social trading platform with copy trading functionality
• Best For: Beginners who want to follow experienced traders

Trading 212

• Commission: 0% commission
• Minimum Deposit: £1
• Key Features: ISA account available, fractional shares
• Best For: Cost-conscious investors wanting tax-efficient investing

Interactive Investor

• Commission: £3.99 per trade
• Minimum Deposit: No minimum
• Key Features: ISA and SIPP available
• Best For: Investors wanting comprehensive pension and ISA options

Hargreaves Lansdown

• Commission: £11.95 per trade
• Minimum Deposit: No minimum
• Key Features: Extensive research tools, ISA and SIPP
• Best For: Investors who value comprehensive research and analysis

AJ Bell

• Commission: £5-£9.95 per trade
• Minimum Deposit: £500
• Key Features: ISA and SIPP, research tools
• Best For: Serious investors with larger portfolios

Tax Implications for UK Investors

Stocks & Shares ISA

UK investors can hold XAIR stock within a Stocks & Shares ISA, providing significant tax advantages:

• No capital gains tax on profits
• No income tax on dividends
• Annual ISA allowance of £20,000 for 2024/25 tax year

Capital Gains Tax

For investments held outside an ISA:

• Annual CGT exemption: £6,000 for 2024/25
• Basic rate taxpayers: 10% CGT on gains above the exemption
• Higher rate taxpayers: 20% CGT on gains above the exemption

Dividend Tax

If Beyond Air pays dividends:

• Annual dividend allowance: £500 for 2024/25
• Basic rate: 8.75% on dividends above allowance
• Higher rate: 33.75% on dividends above allowance

Currency Considerations

Since XAIR trades in USD, UK investors face currency exchange risks. Some brokers offer currency hedging options to mitigate this risk.

Investment Risks and Considerations

Company-Specific Risks

• Clinical Trial Risk: As a clinical-stage company, Beyond Air faces the risk of trial failures
• Regulatory Risk: Medical device approval processes are lengthy and uncertain
• Financial Risk: The company may need additional funding to continue operations
• Competition Risk: Larger pharmaceutical companies may develop competing technologies

Market Risks

• Volatility: Small-cap healthcare stocks are typically highly volatile
• Liquidity Risk: Lower trading volumes may make it difficult to buy/sell large positions
• Currency Risk: GBP/USD exchange rate fluctuations affect returns for UK investors

Sector Risks

• Regulatory Changes: Healthcare regulations can impact the entire sector
• Market Sentiment: Healthcare stocks can be affected by broader sector sentiment
• Patent Risk: Intellectual property challenges could affect the company’s competitive position

Investment Strategy Considerations

Position Sizing

Given the high-risk nature of Beyond Air, consider limiting your position to no more than 2-5% of your total portfolio. This allows for potential upside while limiting downside risk.

Dollar-Cost Averaging

Consider implementing a dollar-cost averaging strategy to reduce the impact of volatility. This involves making regular, smaller investments rather than one large purchase.

Research and Monitoring

Stay informed about:

• Clinical trial results and timelines
• Regulatory approval processes
• Financial statements and cash burn rates
• Management updates and guidance

Frequently Asked Questions

Can I buy XAIR stock in the UK?

Yes, UK investors can buy XAIR stock through various online brokers that provide access to US markets. Most major UK brokers offer this service.

What’s the minimum amount I can invest in XAIR?

This depends on your broker. Some platforms like Trading 212 allow fractional shares with investments as low as £1, while others may require you to buy whole shares.

Are there any restrictions for UK investors buying US stocks?

Generally, there are no restrictions, but you’ll need to complete additional documentation for tax purposes, including W-8BEN forms for US tax treaty benefits.

How are dividends from US stocks taxed in the UK?

Dividends from US stocks are subject to both US withholding tax (typically 15% with treaty benefits) and UK dividend tax, though you can claim credit for US taxes paid.

Should I hold XAIR in an ISA?

If possible, yes. Holding XAIR in a Stocks & Shares ISA eliminates UK capital gains tax and dividend tax, making it more tax-efficient.

What time can I trade XAIR stock from the UK?

NASDAQ trading hours are 2:30 PM to 9:00 PM GMT (during standard time), though some brokers offer extended hours trading.

Is Beyond Air a good investment?

This depends on your risk tolerance and investment objectives. As a clinical-stage company, XAIR carries high risk but also potential for significant returns if their treatments succeed.

Conclusion

Investing in Beyond Air (XAIR) from the UK offers exposure to innovative healthcare technology with significant growth potential. However, it’s crucial to understand the high-risk nature of clinical-stage biopharmaceutical investments. The recent price volatility demonstrates both the opportunities and risks associated with this type of investment.

UK investors have excellent broker options available, with several offering commission-free trading and ISA eligibility for tax-efficient investing. Whether you choose a platform like Trading 212 for cost-effectiveness or Hargreaves Lansdown for comprehensive research tools, ensure your chosen broker aligns with your investment style and needs.

Remember to conduct thorough research, consider your risk tolerance, and never invest more than you can afford to lose in speculative healthcare stocks like XAIR.